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Introduction
 Cancer is one of the leading causes of death worldwide 
(WHO, 2004; 2008). In 2008, it was reported that 
12.7million people were newly diagnosed with cancer 
and that 7.6 million people died of cancer (Ferlay et al., 
2010). In addition, the 5-year global cancer prevalence is 
estimated to be 28.8 million in 2008 (Bray et al., 2013). 
The rates of cancer occurrence in low-and-middle income 
countries are expected to reach as high as 61 percent in 
the world by 2050 (Bray and MÃller, 2006). 
 Patterns of cancer (Jemal et al., 2010; Kamangar et al., 
2006) are very diverse, depending on the region (Kimman 
et al., 2012; Dsouza et al., 2013; Ismail et al., 2013), race 
(McCracken et al., 2007; Ollberding et al., 2011; Siegel et 
al., 2012) and age (Parkin and Fernández, 2006). Regional 
differences were shown in a study by Jemal et al. (2010) 
The study showed that Eastern Europe and Asia have high 
rates of lung cancer in men and that Europe and America 
have high rates of prostate cancer in men. In the future, it 
is expected that more diverse types of cancer will appear 
due to population growth and aging which will in turn 
increase cancer burden. Therefore, we can predict that 
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Abstract
 We attempted to develop an indicator combining incidence with mortality rates (single measure of cancer 
burden, SMCB) and to compare the magnitudes of cancer burden by world region. The SMCB was used to 
measure the size of cancer burden summarizing the incidence and mortality. The incidence and mortality 
were divided in equivalent forms and were split. The criteria dividing the size of cancer burden were used 
as the maximum incidence and mortality by men and women according to the world database, and the value 
corresponding to 10% of each maximum was set as the cut-off value. In SMCB, the size of cancer burden was 
highest for men with lung cancer (SMCB=18) and for women with breast cancer (SMCB=14) in MDR (more 
developed regions) compared to the size of burden in LDR (lower developed regions) (lung, SMCB=11, breast, 
SMCB=8). For men, the size of cancer burden by region was highest in EURO (SMCB=18, lung), followed by 
WPRO (SMCB=16, lung), PAHO (SMCB=14, prostate), AFRO (SMCB=8, prostate) and SEARO (SMCB=7, 
lung). Moreover, for women, the size of cancer burden was greatest in EURO (SMCB=14, breast), followed by 
PAHO (SMCB=13, breast), AFRO (SMCB=11, cervix uteri), EMRO (SMCB=9, breast) or SEARO (SMCB=8, 
cervix uteri) and WPRO (SMCB=7, lung). The summary indicator will help to provide a priority setting for 
reducing cancer burden in  health policy. 
Keywords: Single measure of cancer burden - incidence - mortality - regions
RESEARCH ARTICLE
A Single Measure of Cancer Burden Combining Incidence with 
Mortality Rates for Worldwide Application
Jeong Lim Kim1,2, Kyoung-Hee Cho1,2, Eun-Cheol Park1,2,3*,Woo Hyun Cho4
FDQFHUEXUGHQZLOOEHDQLPSRUWDQWLVVXHLQWKHÀHOGRI
health care (Parkin et al., 2001; Jemal et al., 2011; Siegel 
et al., 2013). 
 It is important for countries to set the priority of cancer 
control as a policy for reducing cancer burden. However, 
prior to prioritization, we should be aware that diagnosed 
cancer and cancer as a cause of death are different from 
each other (Vainio, 2002; Ferlay et al., 2010; Bray et al., 
2012). Cancer incidence and mortality are thought have 
different meanings, and thus, the priority of national 
cancer burden can be changed.
 When cancer incidence is high, cancer mortality is 
relatively lower due to a high survival rate (Parkin and 
Fernández, 2006). In addition, while some cancers have 
high fatality, more cancer cases are being detected early 
through cancer screening tests (Choi et al., 2009; Parkin 
et al., 2005). In this regard, although the incidence and 
mortality of cancer in setting the burden of cancer should 
be measured in combination with each other, they have 
been interpreted separately up to now (Jemal et al., 2008; 
Parkin, 2001). Therefore, we developed a single measure 
of cancer burden (SMCB) combining incidence and 
mortality and compared the world regions.
Jeong Lim Kim et al
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Materials and Methods
Data
 Data were obtained from the GLOBOCAN 2008 
IARC (The International Agency for Research on Cancer) 
and age-standardized (ASRs, per 100,000 populations) 
incidence and mortality rates of cancer (WHO). Cancer 
types included 22 in men and 24 women, and Kaposi 
sarcoma (C46) was excluded from the analysis due to 
LQVXIÀFLHQWGDWDE\UHJLRQ$QDO\VHVLQFOXGHGZRUOGPRUH
developed regions, MDR; less developed regions, LDR, 
and WHO 6 regions (Africa region, AFRO; Americas 
region, PAHO; East mediterranean region, EMRO; Europe 
reion, EURO; South-east Asia region, SEARO; Western 
3DFLÀFUHJLRQ:352
Single measure of cancer burden (SMCB)
 We developed the SMCB, in order to compare the 
VL]HVRIUHJLRQDOFDQFHUEXUGHQ7KH60&%ZDVGHÀQHG
as the summary measuring the incidence and mortality 
from cancer: SMCB=INC+MOR
 The sizes of incidence and mortality was measured the 
HDFKVL]HWRFODVVLÀHGDVHTXLYDOHQWIRUP7KHVL]HVZHUH
based on the maximum incidence and mortality rates by 
men and women according to the world database. The 
value corresponding to 10% of the maximum was set as 
the cut-off value. The sizes of incidence and mortality 
ZHUHGHÀQHGXVLQJWKHPD[LPXPDQGFXWRIIDQGZHUH
FODVVLÀHGLQWRDWRWDORIVWDJHV7KHPD[LPXPLQFLGHQFH
was 66.7, and the maximum mortality was 42.0. 
 7KHVL]HRILQFLGHQFHRUPRUWDOLW\ZDVFODVVLÀHGXVLQJ
the formula below: 
 Where n refers to the size for the incidence or mortality 
vary from 1 to 10. In order to divide the range for each 
of the sizes, 1 was subtracted from n, and the result was 
multiplied by 10 percent of the maximum incidence or 
mortality. The calculated value corresponded to one part 
of range, and in the other part, n was multiplied by 10% 
of the maximum incidence or mortality. 
 Thus, if the size of incidence or mortality was 1, the 
range corresponded to the values up to 10% between the 
minimum and maximum; each maximum was included 
in the 10. This method was applied to incidence and 
mortality, respectively. The higher the size of cancer 
burden, the higher the n. In addition, the more number of 
SMCB increase, the more the cancer burden increase.
Results 
 The overall cancer burden was higher for men than 
for women. In a comparison of incidence and mortality 
by sex, total cancer incidence of the World was 187.1 in 
men and 152.2 in women, and total cancer mortality of 
the World was 116.2 in men and 78.7 in women. Total 
cancer incidence in the more developed regions (MDR; 
men 281.8, women 212.6) was higher than that in the less 
developed regions (LDR; men 144.5, women 125.7). In 
addition, total cancer mortality in the more developed 
regions (MDR; men 130.1, women 78.6) was higher 
than that in the less developed regions (LDR; men 107.9, 
women 77.0). Total cancer incidence for men in the MDR 
was approximately 2-fold higher than that in the LDR. 
However, regarding total cancer mortality in women, there 
was a very small difference between the LDR and MDR.
With regard to total cancer incidence in men and women 
in WHO 6th continents, men had the highest incidence in 
EURO (262.2) and women had the highest incidence in 
PAHO (197.1), while total cancer mortality was the highest 
in both men and women in WPRO. Total cancer incidence 
and mortality were lowest compare to other regions in 
SEARO for men (incidence 90.2, mortality 72.1) and 
in EMRO for women (incidence 91.2, mortality 63.2). 
Cancers with the highest incidence across all continents 
were prostate cancer (66.7) in men and breast cancer (62.8) 
in women. These cancers had the highest incidences in 
PAHO (men) and in EURO (women), respectively. On the 
other hand, cancers that resulted in the highest mortality 
were lung cancer (42.0) in men and cervix uteri cancer 
Table 1. Age-standardized Cancer Incidence and Mortality Rates of Cancer Sites by Sex and Regions
 Regions Male  Female 
            Total           Max                   Min                                         Total         Max         Min
Incidence
 World 187.1  33.8  Lung 1.2  Hodgkins 152.2  38.9  Breast 0.6  Larynx
 More Developed Regions (MDR) 281.8  61.7  Prostate 0.6  Nasopharynx 212.6  66.4  Breast 0.2  Nasopharynx
 Less Developed Regions (LDR) 144.5  27.6  Lung 0.7  Melanoma 125.7  27.1  Breast 0.5  Hodgkins 
 WHO Africa Region (AFRO) 91.2  20.4  Prostate 0.4  Gallbladder, Testis 104.2  30.7  Cervix Uteri 0.3  Larynx
 WHO Americas Region (PAHO) 235.7  66.7  Prostate 0.5  Nasopharynx 197.1  57.2  Breast 0.2  Nasopharynx
 WHO East Mediterranean Region (EMRO) 92.5  12.0  Lung 0.5  Melanoma 91.2  29.3  Breast 0.4  Melanoma 
 WHO Europe Reion (EURO) 262.2  55.3  Prostate 0.6  Nasopharynx 193.1  62.8  Breast 0.2  Nasopharynx
 WHO South-East Asia Region (SEARO) 90.2  16.6  Lung 0.2  Melanoma 107.5  26.1  Breast 0.2  Melanoma  
 :+2:HVWHUQ3DFLÀF5HJLRQ:352   /XQJ  +RGJNLQV   %UHDVW  +RGJNLQV
           Other Pharynx
Mortality 
 World 116.2  29.2  Lung 0.3  Testis, Thyroid 78.7  12.4  Breast 0.3  Hodgkins, Larynx
 More Developed Regions (MDR) 130.1  39.2  Lung 0.3  Nasopharynx, Testis, Thyroid 78.6  15.3  Breast 0.1  Nasopharynx
 Less Developed Regions (LDR) 107.9  24.4  Lung 0.3  Melanoma,  77.0  10.7  Breast 0.3  Hodgkins  
      Testis, Thyroid     Melanoma  
 WHO Africa Region (AFRO) 76.0  14.5  Prostate 0.2  Testis 76.2  21.7  Cervix Uteri 0.2  Larynx
 WHO Americas Region (PAHO) 103.0  28.1  Lung 0.2  Nasopharynx 79.5  15.9  Lung 0.1  Nasopharynx
 WHO East Mediterranean Region (EMRO) 74.5  11.2  Lung 0.3  Melanoma 63.2  16.0  Breast 0.2  Melanoma  
 WHO Europe Reion (EURO) 139.5  42.0  Lung 0.3  Nasopharynx, Thyroid 80.7  16.7  Breast 0.1  Nasopharynx
 WHO South-East Asia Region (SEARO) 72.1  15.2  Lung 0.1  Melanoma of Skin 68.5  13.7  Cervix Uteri 0.1  Melanoma  
 :+2:HVWHUQ3DFLÀF5HJLRQ:352   /XQJ  7HVWLV   /XQJ  +RGJNLQV
*Except Kaposi Sarcoma    
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(21.7) in women. Also, they had the highest values in 
EURO (men) and in AFRO (women). Thus, EURO was 
found to have the highest cancer incidence as well as the 
highest cancer mortality for both men and women. 
 ,Q7DEOHVDQGZHLGHQWLÀHGDSULRULW\RIUHJLRQDO
cancer burden by cancer incidence and mortality, and 
according to the SMCB in order from highest to lowest. 
The sizes of incidence and mortality were calculated by 
applying the calculation method. The SMCB was shown 
to be a result of a combined size of cancer incidence and 
cancer mortality in the same cancer site.
 For the priority of cancer burden, there were varied 
differences in cancer incidence, mortality, and SMCB, 
depending on the cancer site. Ranking of the SMCB 
combining the sizes of incidence and mortality became 
more marked. In particular, the SMCB showed a distinct 
difference in the ratio of existing cancer sites because 
the SMCB’s incidence and mortality were measured in 
HTXLYDOHQWIRUPV,QFLGHQFHPRUWDOLW\DQG60&%LQPHQ
in the world had the highest value priority of lung cancer. 
However, the incidence in men in MDR was highest in 
prostate cancer, and the mortality and SMCB were highest 
in lung cancer. By region, the incidence in men in PAHO 
and EURO had the highest values in prostate cancer, but 
the mortality and SMCB in both PAHO and EURO had 
the highest values in lung cancer. On the other hand, the 
incidence, mortality and SMCB in men in AFRO had the 
highest values in prostate cancer.
 Regarding breast cancer in women, incidence, 
mortality and SMCB had the highest values in the world, 
MDR and LDR, and the results were the same as those 
in EMRO and EURO, while cervix uteri cancer had the 
highest value incidence, mortality and SMCB in AFRO. 
Cancer of priority in PAHO (Breast cancer) had the same 
as incidence and SMCB, while SEARO and WPRO had 
the same as mortality and SMCB. However, in SEARO 
(Cervix uteri cancer) and WPRO (Lung cancer), the same 
results were shown between mortality and SMCB. Based 
on these results (Table 2 and 3), we compared the sizes 
of regional cancer burden worldwide corresponding to 
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Table 2. Priority of Cancer Incidence, Mortality and Single Measure of Cancer Burden (SMCB) by Region (Men)
Regions Ranks Incidence Size Mortality Size SMCB
World 1 Lung 33.8  6  Lung 29.2  7  Lung 13 
 2 Prostate 27.9  5  Liver 14.5  4  Colorectum 7 
 3 Colorectum 20.3  4  Stomach 14.2  4  Prostate 7 
 4 Stomach 19.7  3  Colorectum 9.6  3  Stomach 7 
 5 Liver 16.0  3  Oesophagus 8.5  3  Liver 7 
More Developed Regions (MDR) 1 Prostate 61.7  10  Lung 39.2  10  Lung 18 
 2 Lung 47.1  8  Colorectum 15.1  4  Prostate 13 
 3 Colorectum 37.7  6  Prostate 10.5  3  Colorectum 10 
 4 Stomach 16.7  3  Stomach 10.3  3  Stomach 6 
 5 Bladder 16.3  3  Pancreas 7.9  2  Bladder 5 
Less Developed Regions (LDR) 1 Lung 27.6  5 Lung 24.4  6  Lung 11 
 2 Stomach 20.9  4 Liver 17.3  5  Liver 8 
 3 Liver 18.8  3 Stomach 15.9  4  Stomach 8 
 4 Colorectum 12.1  2 Oesophagus 10.1  3  Oesophagus 5 
 5 Prostate 11.9  2 Colorectum 6.8  2  Colorectum 4 
WHO Africa Region (AFRO) 1 Prostate 20.4  4  Prostate 14.5  4  Prostate 8 
 2 Liver 12.5  2  Liver 12.6  4  Liver 6 
 3 Oesophagus 8.0  2  Oesophagus 7.7  2  Colorectum 4 
 4 Colorectum 7.0  2  Lung 6.3  2  Oesophagus 4 
 5 Lung 6.6  1  Colorectum 5.7  2  Lung 3 
WHO Americas Region (PAHO) 1 Prostate 66.7  10  Lung 28.1  7  Prostate 14 
 2 Lung 34.0  6  Prostate 12.9  4  Lung 13 
 3 Colorectum 23.8  4  Colorectum 8.8  3  Colorectum 7 
 4 Bladder 13.0  2  Stomach 7.8  2  Stomach 4 
 5 Stomach 10.7  2  Pancreas 5.9  2  Leukaemia 4 
WHO East Mediterranean Region 1 Lung 12.0  2  Lung 11.2  3  Lung 5 
(EMRO) 2 Bladder 10.0  2  Stomach 7.8  2  Bladder 4 
 3 Stomach 8.4  2  Bladder 6.7  2  Colorectum 4 
 4 Prostate 7.6  2  Prostate 5.7  2  Prostate 4 
 5 Colorectum 6.7  2  Non-Hodgkin lymphoma 5.2  2  Stomach 4 
WHO Europe Reion (EURO) 1 Prostate 55.3  9  Lung 42.0  10  Lung 18 
 2 Lung 48.1  8  Colorectum 16.3  4  Prostate 12 
 3 Colorectum 35.3  6  Stomach 11.9  3  Colorectum 10 
 4 Bladder 16.5  3  Prostate 11.7  3  Stomach 6 
 5 Stomach 15.1  3  Pancreas 7.7  3  Bladder 5 
WHO South-East Asia Region 1 Lung 16.6  3  Lung 15.2  4  Lung 7 
(SEARO) 2 Lip, oral cavity 8.4  2  Liver 6.2  2  Colorectum 4 
 3 Colorectum 7.4  2  Lip, oral cavity 5.7  2  Liver 4 
 4 Liver 6.7  2  Other pharynx 5.7  2  Lip, oral cavity 4 
 5 Other pharynx 6.6  1  Stomach 5.6  2  Oesophagus 3 
:+2:HVWHUQ3DFLÀF5HJLRQ  /XQJ   /XQJ   /XQJ 
(WPRO) 2 Stomach 39.9  6  Liver 30.9  8  Liver 14 
 3 Liver 34.4  6  Stomach 26.5  7  Stomach 13 
 4 Colorectum 21.3  4  Oesophagus 15.0  4  Colorectum 7 
 5 Oesophagus 18.9  3  Colorectum 9.4  3  Oesophagus 7 
*Except Kaposi Sarcoma
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Table 3. Priority of Cancer Incidence, Mortality and Summary Measure of Cancer Burden (SMCB) by Region 
(Women)
Regions Ranks Incidence Size Mortality Size SMCB
World 1 Breast 38.9  6  Breast 12.4  3  Breast 9 
 2 Cervix uteri 15.2  3  Lung 10.9  3  Lung 6 
 3 Colorectum 14.6  3  Cervix uteri 7.8  2  Cervix uteri 5 
 4 Lung 13.5  3  Colorectum 7.0  2  Colorectum 5 
 5 Stomach 9.1  2  Stomach 6.9  2  Stomach 4 
More Developed Regions (MDR) 1 Breast 66.4  10  Breast 15.3  4  Breast 14 
 2 Colorectum 24.3  4  Lung 13.6  4  Colorectum 7 
 3 Lung 18.8  3  Colorectum 9.7  3  Lung 7 
 4 Corpus uteri 13.0  2  Ovary 5.1  2  Ovary 4 
 5 Ovary 9.3  2  Pancreas 5.1  2  Stomach 4 
Less Developed Regions (LDR) 1 Breast 27.1  5  Breast 10.7  3  Breast 8 
 2 Cervix uteri 17.7  3  Cervix uteri 9.7  3  Cervix uteri 6 
 3 Lung 11.1  2  Lung 9.6  3  Lung 5 
 4 Stomach 9.9  2  Stomach 8.1  2  Colorectum 4 
 5 Colorectum 9.4  2  Liver 7.2  2  Liver 4 
WHO Africa Region (AFRO) 1 Cervix uteri 30.7  5  Cervix uteri 21.7  6  Cervix uteri 11 
 2 Breast 26.5  4  Breast 15.4  4  Breast 8 
 3 Liver 6.1  1  Liver 6.3  2  Liver 3 
 4 Colorectum 4.9  1  Colorectum 4.0  1  Bladder 2 
 5 Oesophagus 4.0  1  Oesophagus 3.8  1  Brain, nervous system 2 
WHO Americas Region (PAHO) 1 Breast 57.2  9  Lung 15.9  4  Breast 13 
 2 Lung 21.9  4  Breast 13.7  4  Lung 8 
 3 Colorectum 18.3  3  Colorectum 7.1  2  Colorectu  5 
 4 Cervix uteri 15.3  3  Cervix uteri 6.5  2  Cervix uteri 5 
 5 Corpus uteri 10.5  2  Pancreas 4.5  2  Ovary 4 
WHO East Mediterranean Region 1 Breast 29.3  5  Breast 16.0  4  Breast 9 
(EMRO) 2 Cervix uteri 9.0  2  Cervix uteri 5.8  2  Cervix uteri 4 
 3 Colorectum 5.4  1  Colorectum 4.1  1  Colorectum 2 
 4 Ovary 4.8  1  Stomach 4.0  1  Bladder 2 
 5 Stomach 4.3  1  Ovary 3.7  1  Brain, nervous system 2 
WHO Europe Reion (EURO) 1 Breast 62.8  10  Breast 16.7  4  Breast 14 
 2 Colorectum 22.7  4  Co orectum 10.3  3  Colorectum 7 
 3 Lung 12.7  2  Lung 10.3  3  Lung 5 
 4 Corpus uteri 12.3  2  Stomach 5.7  2  Stomach 4 
 5 Cervix uteri 10.1  2  Ovary 5.3  1  Ovary 4 
WHO South-East Asia Region 1 Breast 26.1  4  Cervix uteri 13.7  4  Cervix uteri 8 
(SEARO) 2 Cervix uteri 24.4  4  Breast 12.5  3  Breast 7 
 3 Colorectum 6.5  1  Lung 5.3  2  Colorectum 3 
 4 Ovary 6.2  1  Colorectum 4.5  2  Ovary 3 
 5 Lung 5.9  1  Ovary 4.4  2  Lung 3 
:+2:HVWHUQ3DFLÀF5HJLRQ  %UHDVW   /XQJ   /XQJ 
(WPRO) 2 Lung 19.1  3  Stomach 12.4  3  Breast 6 
 3 Stomach 17.3  3  Liver 11.5  3  Stomach 6 
 4 Colorectum 14.7  3  Breast 6.7  2  Colorectum 5 
 5 Liver 12.4  2  Colorectum 6.6  2  Liver 5
*Except Kaposi Sarcoma 
60&%WKURXJKVFKHPDWL]DWLRQ
 2YHUDOO FDQFHUV FRUUHVSRQGLQJ WR 60&%ZHUH
Lung, Prostate, Colorectum, Stomach and Liver cancers 
in men, and Breast, Cervix uteri, Colorectum and Lung 
cancers in women. Among them, Lung cancer and Prostate 
cancer in men and Breast cancer and Cervix uteri cancer 
in women showed more cancer burden by region. For 
cancer burden with respect to the incidence and mortality 
in all regions, men showed the highest incidence in 
PAHO (Prostate=10) and the highest mortality in EURO 
(Lung=10). Women showed the highest incidence in 
EURO (Breast=10) and the highest mortality in AFRO 
(Cervix uteri=6), showing regional differences in the size 
of cancer burden according to incidence and mortality. 
Cancer burden in the aspect of the incidence of prostate 
cancer in men and breast cancer in women showed a 
VLJQLÀFDQWGLIIHUHQFHFRPSDUHGWRFDQFHUEXUGHQLQWKH
aspect of mortality. On the other hand, the cancer burden 
of Lung cancer mortality in men seemed to be higher 
than that of lung cancer incidence in men; however, the 
GLIIHUHQFHZDVQRWVLJQLÀFDQW
 In most regions, it was shown that men showed a more 
diverse distribution of cancer than women; also, cancer 
burden was higher for men than that for women. However, 
women showed a more diverse pattern of cancer compared 
to men in AFRO, SEARO and EMRO. Especially in 
AFRO, the highest burden of cervix cancer (SMCB=11) 
was noted in the region. Lung cancer (SMCB=13) in 
men and Breast cancer (SMCB=9) in women showed 
the highest burden in the world. In MDR and LDR, the 
burdens of these cancers showed the highest values. The 
sizes of Lung cancer (SMCB=18) in men and Breast 
cancer (SMCB=14) in women in MDR were very large 
compared to the sizes of Lung cancer in men and Breast 
cancer in women in LDR (Lung, SMCB=11, Breast, 
SMCB=8). In all regions, cancer burden in men was 
highest in EURO (SMCB=18, Lung), followed by WPRO 
(SMCB=16, Lung), PAHO (SMCB=14, Prostate), AFRO 
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)LJXUH+LJK6LQJOH0HDVXUHRI&DQFHU%XUGHQ60&%E\5HJLRQV
(SMCB=8, Prostate) and SEARO (SMCB=7, Lung). The 
size of cancer burden in women was highest in EURO 
(SMCB=14, Breast), followed by PAHO (SMCB=13, 
Breast), follow by AFRO (SMCB=11, Cervix uteri), and 
EMRO (SMCB=9, Breast) or SEARO (SMCB=8, Cervix 
uteri), and WPRO (SMCB=7, Lung), indicating varied 
differences by region.
Discussion
We compared the sizes of regional cancer burden 
using the Single Measure of Cancer Burden (SMCB). As 
the SMCB developed through combining incidence and 
PRUWDOLW\DPHDVXUHZHUHTXDQWLÀHGE\FRPSRVHWRHTXDO
values since incidence and mortality sizes. 
As the results of the SMCB, there was a regional 
difference in the size of cancer burden and diversity 
according to the cancer site. Lung cancer in men and breast 
cancer in women had a very high burden in most regions. 
Overall, lung cancer in men had the highest cancer burden 
in mortality, and Breast cancer in women had the highest 
cancer burden in incidence. These cancers were also the 
highest priorities in MDR and LDR. These patterns also 
YDULHGE\UHJLRQ7REHPRUHVSHFLÀFOXQJFDQFHULQPHQ
included PAHO, EMRO, EURO, SEARO and WPRO, 
except for AFRO, and Breast cancer in women included 
AFRO, PAHO, EMRO, EURO and SEARO, except 
IRU:3527KHUHIRUH WKHVHFDQFHUVZHUH LGHQWLÀHGDV
important factors that increased the cancer burden around 
the world. 
The SMCB results show that the priority of regional 
FDQFHUEXUGHQZDVVLJQLÀFDQWO\GLIIHUHQWIURPWKHSULRULW\
of incidence and mortality. In particular, the SMCB 
showed the same results when the same cancer incidence 
DQGPRUWDOLW\ZHUH HTXDO UDQNLQJ+RZHYHUZKHQ WKH
UDQNLQJRILQFLGHQFHDQGPRUWDOLW\ZDVHTXDORUWKHFDQFHU
site was different from each other, the SMCB included a 
new cancer or became lower than the ranking of incidence 
DQGPRUWDOLW\7KHUHVXOWZDVFRQÀUPHGWKDWHYHQLIDQ\
one of the rates incidence or mortality were high, the 
ranking of the SMCB was not decide for the direction. 
The incidence of prostate cancer was 27.9, and the 
incidence of stomach cancer was 19.7 in the world, 
indicating that the incidence of prostate cancer was higher 
than the incidence of stomach cancer. On the other hand, 
the mortality of prostate cancer was 7.4, and the mortality 
of stomach cancer was 14.2, indicating that the mortality of 
stomach cancer was higher than the mortality of prostate 
cancer. However, when the incidence and mortality of 
these cancers were added up by the same cancer site, 
the value of prostate cancer was higher than the value of 
stomach cancer. Nevertheless, the SMCB results show 
that prostate cancer and stomach cancer were of the same 
SULRULW\%DVHGRQWKHVHUHVXOWVZHLGHQWLÀHGWKDWFRXOGEH
increased or decreased when the summary measurement 
simply adding the incidence and mortality, if ratio of the 
either part considerably increased or decreased due to the 
characteristics. 
The SMCB is to measure population health. The DALY 
(Disability Adjusted Life-Year) has often been used as an 
indicator of summary measurement for disease burden 
(Gold, 2002; WHO, 2002). The DALY can be regarded as 
a clear indicator because it uses the weight of disability as 
DTXDQWLWDWLYHYDOXHWRPHDVXUHWKHEXUGHQFDXVHGE\WKH
disease, disability and death at the national level (Barker 
and Green, 1996). 
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However, the DALY can occur different the burden 
of disease (WHO, 2001). When the age disability weight 
(Anand and Hanson, 1997) assessment for disability 
(Mont, 2007) and measuring the national burden of disease 
EHFDXVHLWXVHVGLVDELOLW\ZHLJKWWKDWFDQUHDVRQDEO\UHÁHFW
the social preferences of the disease by country besides 
the common GBD (Global burden of disease) disability 
weight. Nevertheless, incidence and mortality are used as 
important indices for evaluating cancer burden (Hakama 
et al., 1975), MI ratio (Mortality-to-Incidence rate ratio) 
can identify trend of cancer but cannot evaluate the size 
of cancer burden(Sant et al., 2006). Moreover, because 
log transformation of data results in a greater ratio, this is 
not different from the separate measurement of incidence 
and mortality. Thus, we developed SMCB to assess the 
indicator size of cancer burden.
In the future, it is expected that the development of 
medical technology and aging of the world population 
will cause increased incidence and decreased mortality 
from cancer (Bray et al., 2012; Jemal et al., 2010). When 
comparing a single indicator that considers the absolute 
size of mortality, like the DALY (Soerjomataram et al., 
2012) and the SMCB which considers the relative size of 
mortality, the SMCB gives prominence to cancer whose 
incidence is high but whose mortality is very low like 
prostate cancer. This indicates that the SMCB can be used 
to suggest important policy implications at this time when 
the character of chronic disease from cancer is enhanced. 
In addition, in regard to the DALY focuses on human 
resources of employment or housework of social has been 
raised continuously criticism that it has give weighted to 
\RXQJSHRSOHH[FHVVLYHO\WKH60&%UHÁHFWLQJDEDODQFHG
age structure can be a remarkable alternative indicator in 
preparation for the aging society.
7KH60&%VKRZHGFODULÀHGUHVXOWVE\ZHDULQJRII
each magnitude for incidence and mortality. In addition, 
cancer site and region were discriminated. The SMCB 
has large implications because it is simple and presents 
a comprehensive draw of priorities and interventions as 
a result of disease status and mortality. Therefore, the 
SMCB considers the validity of calculation of cancer 
burden and has meaning by comparing the results for 
major disease burden. 
+RZHYHUWKH60&%LVQRWDQRIÀFLDOO\VWDQGDUGL]HG
method, and does not include objective criteria. Therefore, 
LWVKRXOGEHQRWHGWKDWLWLVGLIÀFXOWWRDYRLGFRQWURYHUV\
due to such limitations. Nevertheless, the current report 
showed that the incidence in MDR and mortality in 
LDR were present as the main factors of cancer burden 
worldwide. Also, the types of cancer that increased cancer 
burden in various regions in the world were presented. 
Thus, we recommend the SMCB method because of the 
effects relating to unusual priority peculiar differences 
in comparing and assessing the size of cancer burden by 
region. 
We strongly recommend the method of SMCB. 
Worldwide cancer burden caused by increased cancer 
incidence is not a simple national health care problem, 
because this can be the burden for the global economy, as 
well as being the socio-economic burden for the nation. 
Nevertheless, resources are still being continuously wasted 
due to cancer, but cancer burden has not been reduced. 
Cancer can be reduced or controlled by implementing 
evidence-based strategies through prevention and early 
detection. However, because early detection or new 
treatment methods of cancer can cause abrupt changes 
LQLQFLGHQFHDQGPRUWDOLW\LWPD\EHGLIÀFXOWWRSUHGLFW
cancer burden. Therefore, as a prediction plan for cancer 
burden, we should understand the position of the problem 
by setting the priority and determining the direction by 
SUHVHQWLQJ VXIÀFLHQW HYLGHQFH XVLQJ OLPLWHG UHVRXUFHV
(Woolf and Stange, 2006). Through this, we will be able 
to obtain enhanced health outcomes (Thun et al., 2010). 
National policies were very complicated to determine 
whether preferentially solve what due to incurred expenses 
and potential differences even if using the appropriate 
method for any problems. This study can help to assess 
resources allocations and to review information and input. 
It also has a similar meaning as the health indicators of 
the state of Maryland in the United States (“Health people 
7RRONLW$ÀHOGJXLGHWRKHDOWKSODQQLQJµ
,Q WKH IXWXUH UHJLRQDO FDQFHU EXUGHQ LV UHTXLUHG
through the development of a standardized tool that can be 
helpful in conducting a variety of research and guidance 
through continuous monitoring and accurate estimation 
according to the changes of period. Therefore, the single 
measure that we developed will be able to provide 
VSHFLÀFTXDQWLWDWLYHLQIRUPDWLRQIRUGHWHUPLQDWLRQRID
policy to reduce cancer burden. The SMCB can be used 
DVDYDOXDEOHWRROIRUGHFLVLRQPDNLQJUHTXLULQJGLVHDVHV
WKDW FDQ EH LGHQWLÀHG WKURXJK D YDULHW\ RIÀJXUHV DQG
intervention programs as well as an independent tool for 
outlining goals and a vision for effective cancer control. 
The single measure will help to priority setting for 
reducing cancer burden in health policy.  In the future, 
this tool is expected to be utilized for research on cancer 
EXUGHQWRFRUUHFWO\UHÁHFWWKHFKDQJLQJWUHQGVRIFDQFHU
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